Skip to main navigation
Skip to content
Customer Service: 866-788-9007
PHYSICIAN LOGIN   |   CRF LOGIN   
ORDER TEST
Castle Biosciences, Inc.
  • Company
    • About Us
    • History
    • Executive Management
    • Board of Directors
    • Licenses
    • Careers
    • Contact Us
  • Products
    • Cutaneous Melanoma
    • DecisionDx-Melanoma
    • DecisionDx-CMSeq
    • Cutaneous SCC
    • DecisionDx-SCC
    • Uveal Melanoma
    • DecisionDx-UM
    • DecisionDx-UMSeq
    • DecisionDx-PRAME
  • Research & Development
    • Our Approach
    • Tests in Development
    • Suspicious Pigmented Lesions
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Annual Reports
    • Financials & Filings
      • SEC Filings
      • Quarterly Results
    • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
    • Investor Resources
      • Annual Meeting
      • Investor FAQs
      • Investor Contact
      • Email Alerts
  • Scientific Publications
    • DecisionDx-Melanoma
    • DecisionDx-SCC
    • DecisionDx-UM
  • Resources
    • Healthcare Professionals
    • Login/Register
    • Order a Test
    • Reimbursement
    • Patients
    • Overview of our Tests
    • Frequently Asked Questions
    • Insurance Coverage
  • November 23, 2020  Castle Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference

Annual Reports

Annual Reports

2020 Proxy Statement
April 23, 2020
2020 Proxy Statement 313.7 KB
2019 Annual Report
April 23, 2020
2019 Annual Report 4.7 MB
Latest News
  • Castle Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference November 23, 2020
  • Castle Biosciences Announces Publication of Clinical Validation and Utility Data for DecisionDx® DiffDx™-Melanoma for Suspicious Pigmented Lesions November 17, 2020
  • Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx® DiffDx™-Melanoma Tests at American Society of Dermatopathology (ASDP) 57th Virtual Annual Meeting November 12, 2020
  • Castle Biosciences Announces Third Quarter 2020 Results November 9, 2020
  • Castle Biosciences to Present at the Canaccord Genuity 2020 Virtual MedTech & Diagnostics Forum November 5, 2020

Site - Investor Tools

Print Page
Print Page
RSS Feeds
RSS Feeds
Email Alerts
Email Alerts
Investor Contact
Investor Contact
Search
Search
 

Connect with Us

Company

  • About Us
  • History
  • Leadership
    • Executive Management
    • Board of Directors
  • Licenses
  • Careers
  • Contact Us

Products

  • Cutaneous Melanoma
    • DecisionDx-Melanoma
    • DecisionDx-CMSeq
  • Uveal Melanoma
    • DecisionDx-UM
    • DecisionDx-UMSeq
    • DecisionDx-PRAME

Research & Development

  • Our Approach
  • Tests in Development
  • Cutaneous Squamous Cell Carcinoma
  • Suspicious Pigmented Lesions

Latest News & Publications

  • Press Releases
  • Scientific Publications
  • Email Alerts

Resources

  • Healthcare Professionals
    • Login/Register
    • Order A Test
    • Reimbursement
  • Patients
    • Overview of our Tests
    • Frequently Asked Questions
    • Insurance Coverage
Copyright © 2020 Castle Biosciences, Inc. | All Rights Reserved
  • Privacy Policy
  • Terms of Use
  • Contact Us
7ads6x98y